Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

2025.02.25
In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.
Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

2025.02.25
In the evolving landscape of breast cancer treatment, the management of HR+ advanced breast cancer remains a central focus. During the Northern China Breast Cancer Salon – Annual Progress Review, Dr. Zhanhong Chen from Zhejiang Cancer Hospital delivered an in-depth analysis on the stratified treatment approach for HR+ advanced breast cancer. Following the meeting, Oncology Frontier invited Professor Chen to discuss key topics, including the optimal timing for CDK4/6 inhibitor use and the future development of novel targeted therapies.
ASCO GI 2025 | Dr. Zhiqiang Wang: Significant Advantages of Albumin-Bound Docetaxel in Second-Line Treatment for Advanced Gastric Cancer

ASCO GI 2025 | Dr. Zhiqiang Wang: Significant Advantages of Albumin-Bound Docetaxel in Second-Line Treatment for Advanced Gastric Cancer

2025.02.25
As one of the most important academic conferences in the field of gastrointestinal oncology, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) presents a wealth of early-phase drug development data, key registration studies, major research updates, and subgroup analyses every year. These findings represent the latest advancements in the diagnosis and treatment of gastrointestinal cancers. A Phase II multicenter randomized study led by Dr. Zhiqiang Wang from Sun Yat-sen University Cancer Center, which compared the efficacy and safety of albumin-bound docetaxel versus conventional docetaxel in previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma, was selected as an oral abstract (Abstract #333) at this year’s ASCO GI.